MARKER THERAPEUTICS INC (MRKR) Fundamental Analysis & Valuation

NASDAQ:MRKR • US57055L2060

Current stock price

1.3 USD
-0.05 (-3.7%)
Last:

This MRKR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MRKR Profitability Analysis

1.1 Basic Checks

  • MRKR had negative earnings in the past year.
  • MRKR had a negative operating cash flow in the past year.
  • MRKR had negative earnings in each of the past 5 years.
  • MRKR had a negative operating cash flow in each of the past 5 years.
MRKR Yearly Net Income VS EBIT VS OCF VS FCFMRKR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

  • MRKR's Return On Assets of -65.78% is on the low side compared to the rest of the industry. MRKR is outperformed by 62.04% of its industry peers.
  • Looking at the Return On Equity, with a value of -77.75%, MRKR is in line with its industry, outperforming 50.87% of the companies in the same industry.
Industry RankSector Rank
ROA -65.78%
ROE -77.75%
ROIC N/A
ROA(3y)-61.26%
ROA(5y)-61.64%
ROE(3y)-89.71%
ROE(5y)-93.87%
ROIC(3y)N/A
ROIC(5y)N/A
MRKR Yearly ROA, ROE, ROICMRKR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • MRKR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRKR Yearly Profit, Operating, Gross MarginsMRKR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. MRKR Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for MRKR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MRKR Yearly Shares OutstandingMRKR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MRKR Yearly Total Debt VS Total AssetsMRKR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • MRKR has an Altman-Z score of -26.54. This is a bad value and indicates that MRKR is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -26.54, MRKR is not doing good in the industry: 86.90% of the companies in the same industry are doing better.
  • There is no outstanding debt for MRKR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.54
ROIC/WACCN/A
WACCN/A
MRKR Yearly LT Debt VS Equity VS FCFMRKR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • MRKR has a Current Ratio of 6.50. This indicates that MRKR is financially healthy and has no problem in meeting its short term obligations.
  • MRKR has a better Current ratio (6.50) than 64.74% of its industry peers.
  • MRKR has a Quick Ratio of 6.50. This indicates that MRKR is financially healthy and has no problem in meeting its short term obligations.
  • MRKR has a Quick ratio of 6.50. This is in the better half of the industry: MRKR outperforms 65.32% of its industry peers.
Industry RankSector Rank
Current Ratio 6.5
Quick Ratio 6.5
MRKR Yearly Current Assets VS Current LiabilitesMRKR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MRKR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 28.33% over the past year.
EPS 1Y (TTM)28.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-50.98%

3.2 Future

  • MRKR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.23% yearly.
  • Based on estimates for the next years, MRKR will show a very strong growth in Revenue. The Revenue will grow by 152.30% on average per year.
EPS Next Y-70.79%
EPS Next 2Y-6.33%
EPS Next 3Y47.69%
EPS Next 5Y27.23%
Revenue Next Year-12.9%
Revenue Next 2Y150.71%
Revenue Next 3Y241.17%
Revenue Next 5Y152.3%

3.3 Evolution

MRKR Yearly Revenue VS EstimatesMRKR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
MRKR Yearly EPS VS EstimatesMRKR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

1

4. MRKR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MRKR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRKR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRKR Price Earnings VS Forward Price EarningsMRKR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRKR Per share dataMRKR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • MRKR's earnings are expected to grow with 47.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.33%
EPS Next 3Y47.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MRKR Dividend Analysis

5.1 Amount

  • MRKR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MRKR Fundamentals: All Metrics, Ratios and Statistics

MARKER THERAPEUTICS INC

NASDAQ:MRKR (3/27/2026, 8:00:01 PM)

1.3

-0.05 (-3.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18
Earnings (Next)05-13
Inst Owners24.26%
Inst Owner Change17.24%
Ins Owners1.64%
Ins Owner Change0%
Market Cap21.67M
Revenue(TTM)N/A
Net Income(TTM)-14.30M
Analysts82.22
Price Target9.21 (608.46%)
Short Float %4.14%
Short Ratio1.91
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.26%
Min EPS beat(2)30.66%
Max EPS beat(2)73.86%
EPS beat(4)3
Avg EPS beat(4)11.24%
Min EPS beat(4)-87.59%
Max EPS beat(4)73.86%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)41.97%
Min Revenue beat(2)16.75%
Max Revenue beat(2)67.2%
Revenue beat(4)2
Avg Revenue beat(4)1.95%
Min Revenue beat(4)-44.56%
Max Revenue beat(4)67.2%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.09%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.62
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 1.18
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)-1.47
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.28
BVpS1.1
TBVpS1.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -65.78%
ROE -77.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.26%
ROA(5y)-61.64%
ROE(3y)-89.71%
ROE(5y)-93.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.5
Quick Ratio 6.5
Altman-Z -26.54
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.57%
EPS Next Y-70.79%
EPS Next 2Y-6.33%
EPS Next 3Y47.69%
EPS Next 5Y27.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-50.98%
Revenue Next Year-12.9%
Revenue Next 2Y150.71%
Revenue Next 3Y241.17%
Revenue Next 5Y152.3%
EBIT growth 1Y-41.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3430.06%
EBIT Next 3Y-239.79%
EBIT Next 5Y137.29%
FCF growth 1Y27.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.27%
OCF growth 3YN/A
OCF growth 5YN/A

MARKER THERAPEUTICS INC / MRKR Fundamental Analysis FAQ

What is the fundamental rating for MRKR stock?

ChartMill assigns a fundamental rating of 3 / 10 to MRKR.


Can you provide the valuation status for MARKER THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to MARKER THERAPEUTICS INC (MRKR). This can be considered as Overvalued.


How profitable is MARKER THERAPEUTICS INC (MRKR) stock?

MARKER THERAPEUTICS INC (MRKR) has a profitability rating of 0 / 10.


Can you provide the financial health for MRKR stock?

The financial health rating of MARKER THERAPEUTICS INC (MRKR) is 6 / 10.